← Evidence map

TrialHaematologica2014

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

Gang An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

86 papers cite itlatest 60 shown

2014
…
2015
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 24213147